Recent research shows that active vitamin D in its forms promotes replication and Inhibit the spread of Sars-CoV-2 could. The new study results also suggest that the body produces Lumisterol through a chemical reaction with light. This can also effectively block the infection with COVID-19. In addition, the two active ingredients and the metabolites were able to block two specific enzymes (RdRP and Mrpo) that are necessary for the life cycle of SARS-CoV-2.
Use Lumisterol and active vitamin D against coronavirus
In this new study, scientists were able to demonstrate that novel and physiologically relevant derivatives of vitamin D and Lumisterol act against original and mutated strains of SARS-CoV-2. Other benefits of the sun vitamin that researchers highlight are its low cost and easy access to such supplementation. Once vitamin D is consumed, it converts it to various active forms through enzymes known as cytochrome oxidases or CYP enzymes. The authors of this study claim that their results could explain the incidence of some possible mechanisms of the infection. Low levels of vitamin D appear to promote COVID-19 infection and severe disease in certain people. This correlates with other studies that show a link between vitamin D deficiency and the severity of corona infections. Further clinical trials are planned to test the effectiveness of vitamin D and lumisterol as an antiviral therapeutic for COVID-19.
The research team performed a structure-based virtual screening of an in-house library of vitamin D3 and its analogues. The researchers wanted to look for affine binding partners of SARS-CoV-2 Mpro and RdRP. This could help develop potential therapeutics for COVID-19. They first calculated the binding affinities of the available compounds in the library when bound to SARS-CoV-2 Mpro and RdRP. Then the team conducted an interaction to identify better hits. Based on the specific interaction, the scientists identified a set of 10 derivatives from 35 compounds tested. These showed a significant affinity and interaction with the center of Sars-CoV-2. The predicted bond was according to the authors this study when compared to those of recognized antivirals such as danoprevir, lopinavir and ritonavir.